John Volpone - CTi Biopharma Ex Staff
Insider
John Volpone is Ex Staff of CTi Biopharma Corp
| Phone | 206 282 7100 |
| Web | https://www.ctibiopharma.com |
CTi Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.2858) % which means that it has lost $0.2858 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1875) %, meaning that it created substantial loss on money invested by shareholders. CTi Biopharma's management efficiency ratios could be used to measure how well CTi Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.CTi Biopharma Corp currently holds 49.96 M in liabilities. CTi Biopharma Corp has a current ratio of 3.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about CTi Biopharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Ryan Bloomer | Elevation Oncology | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 61 | |
| Erin Cox | Verastem | N/A | |
| Michelle MD | Verastem | 49 | |
| Lauren MD | PDS Biotechnology Corp | 64 | |
| Robert Waltermire | Madrigal Pharmaceuticals | 61 | |
| Jeff York | Seres Therapeutics | N/A | |
| Barry MD | Immunitybio | 60 | |
| Piyush Gupta | Verastem | N/A | |
| RPh PharmD | Elevation Oncology | 40 | |
| Nathalie Riebel | PDS Biotechnology Corp | N/A | |
| Marianne Mancini | Viking Therapeutics | 60 | |
| Hans MD | Immunitybio | 75 | |
| Matthew CPA | PDS Biotechnology Corp | 55 | |
| Richard MD | Corvus Pharmaceuticals | 74 | |
| Remy Sukhija | Madrigal Pharmaceuticals | 52 | |
| Valerie MD | Elevation Oncology | 47 | |
| Robert Weinberg | Verastem | N/A | |
| Mary DiBiase | X4 Pharmaceuticals | 64 | |
| Joseph Ferra | Elevation Oncology | 50 | |
| Janetta Trochimiuk | PDS Biotechnology Corp | 62 | |
Management Performance
| Return On Equity | -10.19 | |||
| Return On Asset | -0.29 |
CTi Biopharma Corp Leadership Team
Elected by the shareholders, the CTi Biopharma's board of directors comprises two types of representatives: CTi Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CTi. The board's role is to monitor CTi Biopharma's management team and ensure that shareholders' interests are well served. CTi Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CTi Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Smith, VP Biometrics | ||
| Ed Bell, Director - Investor Relations | ||
| James Fong, Ex Officer | ||
| Bruce Bennett, VP Operations | ||
| John Volpone, Ex Staff | ||
| David Kirske, CFO, Executive Vice President | ||
| MBA MD, CEO and President |
CTi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CTi Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.19 | |||
| Return On Asset | -0.29 | |||
| Profit Margin | (0.91) % | |||
| Operating Margin | (0.74) % | |||
| Current Valuation | 1.26 B | |||
| Shares Outstanding | 131.88 M | |||
| Shares Owned By Insiders | 5.49 % | |||
| Shares Owned By Institutions | 83.28 % | |||
| Number Of Shares Shorted | 11.27 M | |||
| Price To Earning | (1.68) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in CTi Stock
If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |